ABVC BioPharma, Inc. (ABVC) Stock Score, Valuation & Financial Research

ABVC BioPharma, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ABVC

ABVC BioPharma, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.97. These figures are a research snapshot, not a buy or sell recommendation.

What ABVC BioPharma, Inc. does

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

ABVC BioPharma operates a clinical-stage biopharmaceutical business model that focuses on licensing its core drug and medical device programs to subsidiaries and related parties. By transferring clinical development responsibilities to these entities, the company aims to mitigate direct cash burn while retaining long-term licensing economics and equity participation in the underlying assets.

Products and services

  • The company maintains a pipeline of therapeutic candidates across CNS, oncology, and ophthalmology, alongside medical device development, primarily managed through strategic licensing arrangements.

Customer types

Pharmaceutical and biotechnology companies.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — Unnamed third-party service providers engaged to conduct clinical trials and research activities. Source

Business relationships and partnerships

  • AiBtl BioPharma — A subsidiary/related party to which ABVC has licensed its CNS pipeline for clinical development. Source
  • OncoX BioPharma — A subsidiary/related party to which ABVC has licensed its oncology programs for clinical development. Source
  • ForSeeCon Eye Corporation — A subsidiary/related party to which ABVC has licensed its ophthalmology programs for clinical development. Source

Business strengths to evaluate

  • Asset-backed licensing model that separates development risk from long-term value participation Source

Business risks and research considerations

  • Potential for product liability claims and lack of comprehensive general liability insurance Source
  • Dependence on maintaining strategic partnerships to avoid bearing all development costs and risks Source
  • Risks associated with hazardous materials and environmental compliance Source

Sources: Company research source · AiBtl BioPharma

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ABVC financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.97
Market capitalization:
25.22M (currency not supplied)
Revenue:
USD -795.95K
Net income:
USD -7.9M
Free cash flow:
USD -2.99M
Cash:
USD 31.94K
Total debt:
USD 1.76M
EPS:
USD -0.29

What stands out

  • Free cash flow is USD -2.99M, negative for the stored period.
  • The balance sheet shows USD 31.94K of cash versus USD 1.76M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 1.73M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ABVC

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ABVC fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Is ABVC's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • What specifically needs to improve for ABVC to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of ABVC's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ABVC

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.